Sunshine Biopharma Q1 Revenues Up 2,100%

(24/7 MARKET NEWS) – Sunshine Biopharma Inc. (NASDAQ: “SBFM”) reported, this morning, its 2023 first quarter report, which shows gross revenues of $4,894,053 as of March 31, 2023, an increase of more than 2,100% over the same period in 2022, largely due to the prescription drugs sales of Nora Pharma Inc., a generic pharmaceuticals company that Sunshine Biopharma acquired in October 2022.

Sunshine Biopharma is trading at $0.88, up $0.25 (+66.96%), 575K premarket shares traded.

Its 52-week range is $0.4453 to $2.1977. Its next key inflection point is at $1 and its setup is favorable for a potentially larger run.

24/7 MARKET NEWS, INC Disclaimer

24/7 MARKET NEWS (“24/7 MN”) is dedicated to covering various underreported segments of the stock markets. Our goal is to help you to better understand these markets, but 24/7 MN is neither an investment advisor nor a financial advisor, and no information provided here is to be interpreted as a suggestion to buy or sell stocks or other investment products. All opinions, news, research, analysis, prices or other information contained on, its press releases, or other services are provided for educational purposes only and do not constitute investment advice. You are solely responsible for the investment decisions you make.

Please go to or for further information.

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.